FogPharma and ARTBIO collaborate to co-develop new cancer therapies
The collaboration will combine FogPharma’s Helicon peptide platform with ARTBIO’s AlphaDirect platform to create targeted therapies using the 212Pb isotope. The companies will jointly develop HEARTs against multiple
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.